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Bezafibrate ESI- 360 274 23 18 Fenoprop 
Diclofenac ESI- 294 250 15 12 Fenoprop 
Ketoprofen ESI- 253 209 14 8 Fenoprop 
Naproxen ESI- 229 170 11 16 Naproxen-D3 
Ibuprofen ESI- 205 161 15 8 Fenoprop 
Fenoprop ESI- 267 195 15 13 IS 
Naproxen-D3 ESI- 232 188 11 16 IS 
Sotalol ESI+ 273 255 19 12 Alprenolol 
Atenolol ESI+ 267 145 33 25 Alprenolol 
Acebutolol ESI+ 337 116 37 29 Alprenolol 
Metoprolol ESI+ 268 133 32 24 Alprenolol 
Bisoprolol ESI+ 326 116 33 21 Alprenolol 
Citalopram ESI+ 325 109 20 23 Alprenolol 
Venlafaxine ESI+ 278 121 27 20 Alprenolol 
Carbamazepine ESI+ 237 194 30 19 Dihydrocarbamazepine 
Fluoxetine ESI+ 310 148 13 10 Sertraline-D3 
Sertraline ESI+ 306 275 23 13 Sertraline-D3 
Dihydrocarbamazepine ESI+ 239 194 36 23 IS 








2.4.1 Studied compounds and samples 
















Ampicillin 350.1 159.9 110 12 5.39 0.94 
106.2 20 
Benzylpenicillin 335.1 176.1 100 9 6.7 0.76 
160 9 
Carbamazepine 237.3 194 130 17 6.77 0.84 
179 37 
Cephalexin 348.1 174.1 95 9 5.43 1.23 
158 5 
Clarithromycin 748.5 158.1 165 29 6.83 1.04 
83.1 60 
Cloxacillin 436.1 277.1 100 9 7.31 0.92 
160.1 9 
Doxycycline 445.2 428.1 125 17 6.12 0.92 
98.1 53 
Erythromycin enol ether 716.5 558.4 165 13 6.87 1.08 
158.1 29 
Erythromycin 734.5 576.2 160 16 6.46 1.04 
158 32 




296.1 134.1 110 25 6.22 0.92 
65.1 49 
Oxytetracycline 461.2 443.2 120 9 5.52 1.04 
426.1 17 
Roxithromycin 837.5 679.4 190 17 6.88 0.92 
158.1 37 
Sulfadiazine 251.1 156 105 13 5.34 0.79 
92.1 25 
Sulfamethoxazole 254.1 156 105 13 6.12 1.29 
92.1 25 
Tetracycline 445.2 427 110 8 5.63 1 
410 16 
Trimethoprim 291.2 230.1 130 21 5.42 1.57 
123.1 25 
Tylosin 916.5 174 215 44 6.6 1.21 
101.1 56 
4-epi-tetracycline-D6 451.2 416.2 135 17 5.49 0.55 
Benzylpenicillin-D7 342.1 183.1 90 9 6.69 0.76 
Sulfadiazine-D4 255 96.1 110 25 5.34 0.92 
Trimethoprim-D3 294 123.1 145 25 5.41 1.44 
Cephalexin-D5 353 158 95 5 5.43 0.93 
Carbamazepine-D8 245 202.1 105 20 6.73 1.27 
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q/Q ratio IS 
5 ng l-1 100 ng l-1 
Tetracyclines Tetracycline 20 54 N/A 5 0.993 0.5 
4-epi-tetracycline-D6   Doxycycline 10 88 N/A 19 0.994 0.37 
  Oxytetracycline 5 113 16 17 0.989 0.39 
ß-lactams Benzylpenicillin 1 92 15 3 0.996 0.9 
Benzylpenicillin-D7 
  Cloxacillin 1 99 7 10 0.992 0.98 
  Ampicillin 1 102 11 6 0.992 0.55 
Cephalexin-D5 
  Cephalexin 1 92 18 7 0.992 0.52 
Sulfonamides Sulfadiazine 10 88 N/A 2 0.993 0.87 
Sulfadiazine-D4 
  N-acetyl sulfadiazine 5 150 13 4 0.996 0.67 
  Trimethoprim 5 95 3 12 0.991 0.75 Trimethoprim-D3 
  Sulfamethoxazole 1 29 11 (n=9) 10 0.996 0.92 
Sulfadiazine-D4 
  N-acetyl sulfamethoxazole 10 36 N/A 9 0.997 0.69 
Macrolides Erythromycin 1 135 7 15 0.999 0.52 
Trimethoprim-D3 
  Erythromycin enol ether 10 63 N/A 9 0.998 0.96 
  Roxithromycin 50 142 N/A 9 0.991 0.65 
4-epi-tetracycline-D6   Clarithromycin 5 77 5 11 0.991 0.32 
  Tylosin 1 90 39 11 0.991 0.52 







Table 7 Antibiotics concentrations in the studied rivers. 
 
Compound class Target compound 
Mean (ng l-1) and RSD (%) at the sampling points 
River Kerava (upstream) River Vantaa (downstream) 
River Vantaa (WWTP 
discharge) 
Tetracyclines 
Oxytetracycline <LOQ <LOQ <LOQ 
Doxytetracycline <LOQ <LOQ <LOQ 
Tetracycline <LOQ <LOQ <LOQ 
ß-lactams 
Cloxacillin 45 ±2.1 <LOQ <LOQ 
Cephalexin <LOQ 13 ±4.2 35 ±3.7 
Ampicillin <LOQ <LOQ <LOQ 
Benzylpenicillin <LOQ <LOQ <LOQ 
Sulfonamides 
Sulfadiazine <LOQ 18 ±2.2 66 ±2.6 
N-acetyl sulfadiazine <LOQ <LOQ <LOQ 
Trimethoprim  <LOQ 21 ±4.8 81 ±1.7 
N-acetyl sulfamethoxazole <LOQ <LOQ <LOQ 
Sulfamethoxazole <LOQ <LOQ 5 ±3.7 
Macrolides 
Erythromycin <LOQ 5 ±1.3 14 ±3.0 
Clarithromycin <LOQ 8 ±2.0 26 ±0.7 
Roxithromycin <LOQ <LOQ 10 ±1.6 
Tylosin <LOQ <LOQ <LOQ 
Erythromycin enol ether <LOQ <LOQ <LOQ 
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